Image of Jennifer J. Furin

Jennifer J. Furin, MD, PhD

Lecturer on Global Health and Social Medicine

Jennifer Furin, MD, PhD, is an infectious diseases clinician and a medical anthropologist who focuses on global health. She received her PhD in Medical Anthropology from the University of California at Los Angeles in 1995 and her MD from Harvard Medical School in 1999. She completed her residency in internal medicine at Brigham and Women’s Hospital in 2002 and her fellowship in infectious diseases at University Hospitals Case Medical Center (Cleveland) in 2004. Dr. Furin is engaged in clinical and program work and operational research to support the treatment of multidrug-resistant tuberculosis and HIV. She has been fighting drug-resistant TB since 1995 when she began working in Lima, Peru with Partners In Health. She has significant global experience and has done work in Haiti, Peru, Russia, Lesotho, South Africa, Georgia, Bangladesh, Swaziland, and Tajikistan. She is also a member of the Tuberculosis Transformation Science Committee of the AIDS Clinical Trials Group. She serves as a high-level consultant for a number of National TB Programs, WHO, USAID, and Médecins Sans Frontières


Dr. Furin is also an adjunct assistant professor in the Department of Anthropology at Case Western Reserve University

Dr. Furin is the director of Clinical Capacity Building for the Sentinel Project on Pediatric Drug-Resistant Tuberculosis

Dr. Furin is participating in teaching and research in the Department's Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

The problem with vitamin D supplementation for tuberculosis.
Authors: Authors: Reuter A, Furin J.
Lancet HIV
View full abstract on Pubmed
Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.
Authors: Authors: Wasserman S, Furin J.
Am J Respir Crit Care Med
View full abstract on Pubmed
Can Green Light Committees help "end TB"?
Authors: Authors: Furin J.
Int J Tuberc Lung Dis
View full abstract on Pubmed
SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis.
Authors: Authors: Dousa KM, Malavade SS, Furin J, Gripshover B, Hatszegi M, Hojat L, Saade E, Salata RA.
View full abstract on Pubmed
Treating drug-resistant tuberculosis infection: no more excuses.
Authors: Authors: Reuter A, Furin J.
Clin Infect Dis
View full abstract on Pubmed
Preventing tuberculosis in children: A global health emergency.
Authors: Authors: Reuter A, Seddon JA, Marais BJ, Furin J.
Paediatr Respir Rev
View full abstract on Pubmed
Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa.
Authors: Authors: Mohr-Holland E, Reuter A, Furin J, Garcia-Prats A, De Azevedo V, Mudaly V, Kock Y, Trivino-Duran L, Isaakidis P, Hughes J.
View full abstract on Pubmed
"A very humiliating illness": a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa.
Authors: Authors: Furin J, Loveday M, Hlangu S, Dickson-Hall L, le Roux S, Nicol M, Cox H.
BMC Public Health
View full abstract on Pubmed
Barriers and solutions to finding rifampicin-resistant tuberculosis cases in older children and adolescents.
Authors: Authors: Mohr-Holland E, Apolisi I, Reuter A, de Azevedo V, Hill J, Matthee S, Seddon JA, Isaakidis P, Furin J, Trivino-Duran L.
Public Health Action
View full abstract on Pubmed
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
Authors: Authors: McKenna L, Furin J.
Lancet Respir Med
View full abstract on Pubmed